PCSK9 Inhibition After Heart Transplantation
| Status: | Not yet recruiting |
|---|---|
| Conditions: | Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 12 - Any |
| Updated: | 5/27/2018 |
| Start Date: | September 2018 |
| End Date: | September 2023 |
| Contact: | Study Team |
| Email: | luikart@stanford.edu |
| Phone: | 650-724-2883 |
The focus of this study is to test the safety and efficacy of the PCSK9 inhibitor, alirocumab
when administered early after heart transplantation (HT).The main objective of this project
is to test the safety and impact on cardiac allograft vasculopathy (CAV) of alirocumab when
given early after HT.
when administered early after heart transplantation (HT).The main objective of this project
is to test the safety and impact on cardiac allograft vasculopathy (CAV) of alirocumab when
given early after HT.
Inclusion Criteria:
- Heart Transplant recipient
Exclusion Criteria:
- impaired liver function
We found this trial at
1
site
Stanford University Stanford University, located between San Francisco and San Jose in the heart of...
Click here to add this to my saved trials
